Cartesian Therapeutics (RNAC) Enterprise Value (2016 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Enterprise Value for 11 consecutive years, with -$125.1 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 41.14% to -$125.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$125.1 million through Dec 2025, up 41.14% year-over-year, with the annual reading at -$125.1 million for FY2025, 41.14% up from the prior year.
- Enterprise Value for Q4 2025 was -$125.1 million at Cartesian Therapeutics, up from -$143.4 million in the prior quarter.
- The five-year high for Enterprise Value was -$76.9 million in Q4 2023, with the low at -$219.2 million in Q3 2024.
- Average Enterprise Value over 5 years is -$136.6 million, with a median of -$136.6 million recorded in 2021.
- The sharpest move saw Enterprise Value soared 45.64% in 2023, then plummeted 176.44% in 2024.
- Over 5 years, Enterprise Value stood at -$128.1 million in 2021, then fell by 5.11% to -$134.6 million in 2022, then surged by 42.86% to -$76.9 million in 2023, then plummeted by 176.44% to -$212.6 million in 2024, then skyrocketed by 41.14% to -$125.1 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$125.1 million, -$143.4 million, and -$160.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.